This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by White, D. Articles by Hughes, T. Search for Related Content PubMed PubMed Citation Articles by White, D. Articles by Hughes, T. Social Bookmarking                            What's this?

Measurement of In Vivo BCR-ABL Kinase Inhibition to Monitor Imatinib-Induced Target Blockade and Predict Response in Chronic Myeloid Leukemia

Deborah White, Verity Saunders, Andrew Grigg, Chris Arthur, Robin Filshie, Michael F. Leahy, Kevin Lynch, L. Bik To, Timothy Hughes

From the Division of Hematology, Institute of Medical and Veterinary Science & Hanson Institute; The University of Adelaide; and Royal Adelaide Hospital, Adelaide, South Australia; Royal Melbourne Hospital, Melbourne; Royal North Shore Hospital, Sydney; St Vincent's Hospital, Melbourne; Fremantle Hospital, Perth; and Novartis Pharmaceuticals Australia Pty Ltd, Sydney, Australia

Address reprint requests to Deborah White, Division of Hematology, Institute of Medical and Veterinary Science & Hanson Institute, PO Box 14, Rundle Mall Post Office, Adelaide, Australia 5001; e-mail: deb.white{at}imvs.sa.gov.au

Purpose Intrinsic sensitivity to imatinib, based on measurement of inhibitory concentration 50% for imatinib, is variable in untreated patients with chronic myeloid leukemia (CML). This suggests that patient-tailored dosing may be more rational than a fixed dose for all. Dose optimization potentially could be based on accurate measurement of the level of BCR-ABL kinase inhibition achieved in vivo.

Patients and Methods In vivo kinase inhibition was measured by calculating the reduction in protein (p) -Crkl level in mononuclear blood cells taken from 49 CML patients at weekly intervals after imatinib therapy was commenced.

Results Greater than 50% inhibition (> 50% reduction in p-Crkl from baseline) was achieved by 21% of patients by days 7 to 14 (and maintained in all patients on days 21 to 28) and an additional 24% of patients achieved more than 50% inhibition by days 21 to 28. Thus, overall 45% of patients achieved more than 50% inhibition. All of these patients achieved major molecular responses by 24 months compared with 56% of the patients who failed to achieve 50% kinase inhibition (P < .001). Patients with less than 50% kinase inhibition were also more likely to have suboptimal responses.

Conclusion In vivo BCR-ABL kinase inhibition can be assessed in the first month of imatinib therapy and may provide a valuable guide to optimization of dosage. The extent of BCR-ABL kinase inhibition is an excellent predictor of cytogenetic and molecular response. These observations suggest that dose adjustment based on in vivo measurements of drug-induced target inhibition could be applied in settings beyond imatinib and may be a more effective approach than using one dose for all patients in targeted anticancer therapy.

Supported in part by a grant from the Cancer Council of Australia, with additional support from Novartis Australia, the Australasian Leukemia Lymphoma Group, Novartis, and Amgen Pharmaceuticals.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. S. Khorashad, S. Wagner, L. Greener, D. Marin, A. Reid, D. Milojkovic, H. Patel, S. Willimott, K. Rezvani, G. Gerrard, et al. The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib Haematologica, June 1, 2009; 94(6): 861 - 864. [Abstract] [Full Text] [PDF]

				D. Bixby and M. Talpaz Imatinib As Frontline Therapy for Patients with Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia ASCO Educational Book, January 1, 2009; 2009(1): 395 - 401. [Abstract] [Full Text] [PDF]

				C. H. Chau, O. Rixe, H. McLeod, and W. D. Figg Validation of Analytic Methods for Biomarkers Used in Drug Development Clin. Cancer Res., October 1, 2008; 14(19): 5967 - 5976. [Abstract] [Full Text] [PDF]

				R. W. Alfano, S. H. Leppla, S. Liu, T. H. Bugge, M. Herlyn, K. S. Smalley, J. L. Bromberg-White, N. S. Duesbery, and A. E. Frankel Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells Mol. Cancer Ther., May 1, 2008; 7(5): 1218 - 1226. [Abstract] [Full Text] [PDF]

				P. La Rosee, S. Holm-Eriksen, H. Konig, N. Hartel, T. Ernst, J. Debatin, M. C. Mueller, P. Erben, A. Binckebanck, L. Wunderle, et al. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib Haematologica, May 1, 2008; 93(5): 765 - 769. [Abstract] [Full Text] [PDF]